teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12...910111213141516171819...3132»
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells. (Pubmed Central) -  Dec 25, 2021   
    Finally, we showed that the susceptibility of memory CD8 T cells to DHODH inhibition was not related to impaired metabolism. Overall, these findings demonstrate that the clinical efficacy of teriflunomide results partially in the specific susceptibility of memory CD8 T cells to DHODH inhibition in patients with RRMS and strengthens active roles for these T cells in the pathophysiological process of MS.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Observational data, Journal, HEOR:  The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis. (Pubmed Central) -  Dec 24, 2021   
    Our study found a decrease in QoL correlated with teriflunomide, which deserves further investigation. This experience demonstrates that joint action between scientific society and students association can be successful in conducting a no-profit multicenter observational study in a real-world setting.
  • ||||||||||  Ponvory (ponesimod) / J&J
    Journal:  Ponesimod to treat multiple sclerosis. (Pubmed Central) -  Dec 23, 2021   
    Results from the OPTIMUM phase III trial demonstrated the superiority of ponesimod over teriflunomide on disease activity markers, without unexpected safety concerns...Ponesimod was recently approved in both the U.S. and E.U. for the treatment of relapsing forms of multiple sclerosis. This review summarizes the pharmacological characteristics of ponesimod and the main studies that led to its approval.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal, HEOR, Real-world evidence:  Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials? (Pubmed Central) -  Dec 16, 2021   
    These include fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab and ocrelizumab...From the safety point of view, observational studies revealed new adverse events, mostly in the area of bacterial and opportunistic infections, not seen in the relative registration programme. This is a very important gain because it allows to elaborate appropriate strategies to prevent and handle the risks.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19. (Pubmed Central) -  Dec 7, 2021   
    Remdesivir and its active metabolite (GS-441524) were used as the active references for the comparison and evaluation purpose...In conclusion, the current research paved the way to practically prove the hypothetical theory of the promising abilities of teriflunomide to successfully attack the SARS-CoV-2 particles and inhibit their replication in a triple mode of action through integrating the newly-discovered nCoV-RdRp-inhibiting properties with the previously-known two anticoronaviral mechanisms of action. Based on the previous interesting facts and results, the triple SARS-CoV-2/sextet COVID-19 attacker teriflunomide can further undergo in vitro/in vivo anti-COVID-19 assays together with preclinical/clinical studies and trials in an attempt to evaluate and prove its comprehensive pharmacological activities against the different SARS-CoV-2 strains to be effectively used in COVID-19 therapy in the very near future.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Review, Journal:  Teriflunomide: Pediatric First Approval. (Pubmed Central) -  Nov 29, 2021   
    On 18 June 2021, teriflunomide received its first approval in this indication in pediatric patients aged ≥ 10 years in the EU. This article summarizes the milestones in the development of teriflunomide leading to this first pediatric approval for relapsing-remitting MS.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Ocrevus (ocrelizumab) / Roche, Biogen
    [VIRTUAL] COVID-19 Vaccine Antigenicity in the Setting of MS Disease Modifying Treatments () -  Nov 20, 2021 - Abstract #CMSC2021CMSC_680;    
    First, analyzing immunogenicity as a prevalence measure (ie, % of patients mounting antibodies) vs mean antibody titers can impact conclusions. There are marked differences between DMTs with regards to COVID vaccine antibody immunogenicity.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful. (Pubmed Central) -  Nov 2, 2021   
    The objective is to stimulate a discussion about the need to improve research strategies. The discovery of new drugs studied without personalized criteria does not allow for useful advances in knowledge.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Clinical, FDA event, Review, Journal:  Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. (Pubmed Central) -  Oct 31, 2021   
    The most common breast cancer drugs that regulate or inhibit the MAPK pathway may include Farnesyltransferase inhibitors (FTIs), Sorafenib, Vemurafenib, PLX8394, Dabrafenib, Ulixertinib, Simvastatin, Alisertib, and Teriflunomide. In this review, we will discuss the roles of the MAPK/RAS/RAF/MEK/ERK pathway in BC and summarize the FDA-approved prescription drugs that target the MAPK signaling pathway in women with BC.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Pregnancy and multiple sclerosis: an update. (Pubmed Central) -  Oct 28, 2021   
    Active, not recruiting --> Completed The evidence of potential fetotoxicities and adverse pregnancy outcomes associated with DMTs is increasing, although more research is needed to evaluate the safety of drugs and to track long-term health outcomes for the mother and the child.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Observational data, Journal:  Therapeutic inertia in relapsing-remitting multiple sclerosis. (Pubmed Central) -  Oct 22, 2021   
    TI is a topic rarely addressed in MS and this work highlights the importance of therapeutic optimization in these patients. Further studies should be held to explore the factors that influence TI once they have a great impact on therapeutic decisions.
  • ||||||||||  leflunomide / Generic mfg.
    [VIRTUAL] WHEN TO LEAVE THE LEFLUNOMIDE () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_704;    
    We describe the importance of recognizing some less commonly seen manifestations of LEF toxicity. Early discontinuation of LEF is key, and a cholestyramine washout should be performed if the clinical presentation is severe.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies () -  Oct 8, 2021 - Abstract #CMSC2021CMSC_624;    
    This observation is in line with reports from rheumatology and other medical fields where either de-novo psoriasis or exacerbation of known psoriasis have been observed in association with B cell depletion. Further research is needed to identify an actual excess risk and unravel the underlying immunopathologic mechanisms.
  • ||||||||||  Ponvory (ponesimod) / J&J
    [VIRTUAL] MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity () -  Oct 8, 2021 - Abstract #CMSC2021CMSC_578;    
    NNT itself is limited by clinical trial differences, and there is an increasing need to develop novel techniques to compare the efficacy of MS DMTs across clinical trials. Regardless of the EDA/NEDA status at week 108, ponesimod benefit over teriflunomide on MS- related fatigue remained the same, suggesting that addressing classical clinical efficacy (NEDA/EDA definition) might not be sufficient in addressing fatigue in RMS patients.